Pricing Log in Create free account
Saturday 17 October 2026 Export WST’s income statement to Excel — free account

West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

382.92 0.10 −0.03%
Market cap
$27.0B
P/E
48.7×
Fwd P/E
37.3×
Dividend yield
0.23%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

West Pharmaceutical Services, Inc. (WST) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 27 added · 5 removed · 26 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jul 14, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K May 31, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K/A May 7, 2026 1.05 Material cybersecurity incident; 9.01 Financial statements and exhibits
8-K May 7, 2026 1.05 Material cybersecurity incident; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 4, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 9, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 2 added · 3 removed · 18 modified
1A: 6 added · 1 removed · 14 modified
7: 9 added · 12 removed · 28 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 23, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.